-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicenna Therapeutics Q2 FY27 net loss narrows 18% year over year to $4 million

PUBT·11/17/2026 12:45:36
Listen to the news
Medicenna Therapeutics Q2 FY27 net loss narrows 18% year over year to $4 million
  • Medicenna Therapeutics’ second-quarter FY27 net loss narrowed 18% year over year to $4 million.
  • Operating costs fell 25% year over year to $4.1 million.
  • Cash and cash equivalents declined 35% from June 30 to $3.7 million at September 30, 2026.
  • Existing cash cannot fund planned operations over the next twelve months, requiring additional financing.
  • MDNA11’s ABILITY-1 trial completed enrollment with 152 patients; its biomarker-enriched gastrointestinal cancer cohort achieved a 40% objective response rate.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170745PRIMZONEFULLFEED9879348) on November 17, 2026, and is solely responsible for the information contained therein.